Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 in Huntington's Disease Chorea
NCT01019473Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2009
- Primary completion
- Aug 2011
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of mavoglurant in Huntington's disease (HD) and chorea (2 arms), sponsored by Novartis. Primary endpoint: Unified Huntington's Disease Rating Scale Maximal Chorea at 28 days. Started Nov 2009; status: terminated.
02
Drugs
mavoglurant
03
Conditions
Huntington's disease (HD)chorea
Beyond the preview
Go deeper on NCT01019473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01019473.